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Article Information  ABSTRACT 
Received: 19th August 2018  The American Medical Research Community sounded a heavy metal warning against some 
herbo-mineral Ayurvedic formulations from Indian System of Medicine sold in United States of 
America. The products were rejected by Unites States Food and Drug Administration due to the 
presence of high level of lead, mercury and arsenic as impurities, marked as toxicity inducers. 
This work has been design to investigate whether the toxicity produced by Mahasudarshan 
churna is due to the results of lipid peroxidation, as oxidative degradation of phospholipids is 
one of the causes of drug-induced toxicity. The level of malondialdehyde, reduced glutathione 
and nitric oxide were estimated in control, drug-treated, drug-antioxidant treated and only 
antioxidant-treated group at two hours and six hours of incubation time in goat liver 
homogenates. Ascorbic acid was used to compare the oxidative potentials of Mahasudarshan 
churna. The level of malondialdehyde was found to be decreased in the drug-treated, drug-
antioxidant treated and only antioxidant treated group where as the level of reduced glutathione 
and nitric oxide increased when compared to control. Above all the Drug-antioxidant treated 
group showed maximum anti-oxidant properties when compared to other groups. The study was 
designed to investigate the lipid peroxidation induction capacity of Mahasudarshan churna as 
consequences of its toxicity and found that lipid peroxidation is not the contributing factor. 
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INTRODUCTION 
Ayurveda is a form of Indian system of medicine was practiced 
from ancient to heal or cure many acute or chronic diseases. 
Rasashastra which is a branch of ayurveda describes how 
metals, gems, minerals, and poisons can be used for 
manufacturing of ayurvedic formulations. These formulations 
are commonly known as herbo-mineral formulations. They are 
used to treat diseases results from the deficiency or imbalance 
of metallic micro nutrients in body [1-2].
 
Though it is believed 
that ayurvedic formulations are safe when compared to 
Journal of Applied Pharmaceutical Research 7 (2); 2019: 7 – 15 Pandit et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| April – June 2019 | Volume 7 Issue 2 |   8 
allopathic formulations, but due to lack of evidence based on 
its standards profile, quality and safety, it is not approved by 
the Food and Drug Administration (FDA) of United Sate (US) 
[3]. As herbo-mineral formulations contains heavy metals as an 
active ingredients it can potentially harm our vital body 
functions which may includes damage to the brain, kidney and 
lungs, when consumed more than the limit prescribe by World 
Health Organization (WHO).  
 
The American Medical Research Community has sounded a 
warning against the herbal products of Indian system of 
medicine sold in US contain dangerous level of lead, mercury 
and arsenic as heavy metals. Herbo-mineral formulations like 
Mahasudarshan churna, bal guti, bal chamcha, bal soguthi, 
mahalakshmi vilas ras etc are rejected by US FDA as they 
produce mild to moderate toxicities [4-5].  
 
A substance capable of producing therapeutic effects can yield 
undesired or adverse effects also. “Side effects” and “toxic 
effects” are the two dimensions of adverse effects. Toxicity is 
always dose-related, whereas side effect might not be dose-
related [6]. Many mechanisms developed to illustrate drug-
induced lipid peroxidation. Generation of peroxide free radicals 
during the therapy is one of them. Peroxide free radicals are 
oxygenated species generated due to the oxidation of 
membrane phospholipids [7-8].  
As drugs are the potential candidate to induce lipid 
peroxidation, they might contribute to drug-induced toxicity as 
an effect of lipid peroxidation [9]. In this project work we are 
going to find out whether the toxicity produced by this 
formulations are due to the results of lipid peroxidation or not. 
As heavy metals have the tendency to produce peroxide free 
radicals when interact with lipids, antioxidant can be a useful 
tool to prevent drug induced lipid peroxidation [10-11]. Goat 
liver is selected as in-vitro model for induction of lipid 
peroxidation. Mahasudarshan churna, a herbomineral formation 
is selected as drug for the study. Ascorbic acid is selected as 
natural antioxidant. 
 
Ascorbic acid is a monosaccharide found both in animals and 
plants. It works as a reducing agent [12-14]. Ascorbic acid was 
proved as an effective antioxidant to reduce the lipid 
peroxidation prompted by gentamycin, cisplatin, ceftazidime, 
flutamide, and tobramycin [15-19]. Estimation of MDA, GSH 
and NO was performed in goat liver homogenates. MDA is an 
oxidative by product of arachidonic acid. The level of MDA 
increases during lipid peroxidation. GSH and NO give 
protection against lipid peroxidation. The decreased level of 
GSH and NO than usual indicated the commencement of lipid 
peroxidation [20-25]. 
 
MATERIALS & METHODS 
Materials 
N-1-napthylethylenediamine dihydrochloride, thiobarbituric 
acid, 5,5’-Dithiobis-(2-nitrobenzoic acid); ascorbic acid, 
reduced glutathione; 1,1,3,3-tetraethoxypropane; trichloroacetic 
acid, sodium hydroxide, potassium dihydrogen phosphate and 
sodium nitrite were purchased from Loba Chemie Private 
Limited, India. Mahasudarshan churna of Shree Baidyanath 
Ayurved Bhawan Pvt. Ltd. were purchased from local 
ayurvedic medical store, India. Analytical grade reagents were 
used in this work. 
 
Methods 
Preparation of goat liver homogenate
 
[16] 
Goat liver was obtained from Raipur Municipal Corporation 
(RMC) authorized slaughterhouse. It was selected due to its 
availability and similarities with the human live. The goat liver 
was harvested and cut into pieces with a sharp knife. Then the 
pieces were dipped into a germ-free conical flask previously 
filled with phosphate buffer (pH 7.4) solution. Before preparing 
the homogenates, the liver pieces were removed from the 
container and rinsed well with newly prepared phosphate buffer 
solution of pH 7.4. After that, the liver was ground into 
homogenates in the ratio of 1 g/ml of same phosphate buffer. 
The homogenate was then divided into four parts of equal 
volume and treated as mentioned below. 
 
One of the portions was treated with 1 ml of distilled water and 
marked as a control group (C). The second portion of the 
homogenate was treated with Mahasudarshan churna at a dose 
of 55.12 mg/g of tissue homogenates. This group was marked 
as drug-treated group (D). The third portion was treated with 
Mahasudarshan churna and ascorbic acid at a dose of 55.12 
mg/g and 0.166 mg/g of tissue homogenates respectively. It 
was kept as a drug- and antioxidant-treated group (DA). The 
fourth portion was incubated with ascorbic acid at a dose of 
0.166 mg/g of homogenate and kept as an antioxidant-treated 
group (A). Then the samples were shaken for 4 h using an 
orbital shaker. 
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Estimation of MDA level from the tissue homogenate samples 
The extent of peroxidation of lipids in the samples was 
determined by measuring the level of MDA using 
thiobarbituric acid (TBA) method [26]. The extent of MDA in 
the samples was estimated at 2 h and 4 h of incubation. After 
each specified hour of incubation 2.50 ml of an incubated 
mixture was poured into the centrifuge tubes (5 centrifuge 
tubes for each set, i.e. for C, D, DA, and A) and 2.50 ml of 10 
% w/v TCA solution was mixedwith each tube to precipitate 
protein. The samples were then centrifuged at 3000 r.p.m for 
30 min, and the supernatant was separated through filtration.  
Then 2.50 ml of the filtrate was taken in a stoppered glass tube 
(5 stoppered glass tubes for each set, i.e. for C, D, DA, and A). 
5.00 ml of 0.002 M thiobarbituric acid (TBA) solution was 
added to each tubes. The volume was adjusted to 10.00 ml by 
the addition of distilled water. The tubes were then kept on a 
water bath and boiledtill a pink colour developed.The 
absorbance of solutions were measured and recorded at 530 nm 
against a solution prepared by 5.00 ml of TBA solution and 
5.00 ml of distilled water. Shimadzu UV-1800 Double Beam 
Spectrophotometer was used to measure the absorbance. The 
concentration of MDA present in the test samples were 
calculated from the standard calibration curve. 
1,1,3,3-Tetrahydroxy propane (TEP) was used to construct the 
standard calibration curve. A series of standard solution were 
prepared by mixing 5.00 ml of freshly prepared TBA solution 
with several aliquots of standard TEP solution in graduated 
tubes. The volume of the tubes was then made up to 10.00 ml 
with distilled water. The tubes were then boiled in a steam bath 
form about 30 min, cooled, and their absorbances were 
recorded at 530 nm. The blank solution was prepared by 
mixing 5.00 ml of TBA solution and 5.00 ml of distilled water. 
Obsersed absorbances were plotted against concentrations to 
obtain the best-fit equation i.e. y=0.006x, where y=absorbance, 
x=concentration. The value of R
2
 was found to be 0.992 & 
standard error mean (sem)=0.015. 
 
Estimation of NO level from the tissue homogenate samples 
Estimation of NO was done as mentioned in Griess’s method 
[27-28]. The level of NO in the samples was determined at 2 h 
and 4 h of incubation. After each specified hour of incubation 
2.50 ml of an incubated mixture was poured into the centrifuge 
tubes (5 centrifuge tubes for each set, i.e. for C, D, DA, and A) 
and 2.50 ml of 10 % w/v TCA solution was added to each tube 
for the precipitation of protein. The samples were then 
centrifuged at 3000 r.p.m for 30 min, and the supernatant was 
separated through filtration.5.00 ml of the filtrate was taken in 
stopper glass tube (5 stoppered glass tubes for each set, i.e. for 
C, D, DA, and A)and 0.50 ml of Griess reagent was added into 
it. Griess reagent was prepared by mixing 1:1 ratio of 
sulphanilamide (1 % w/v in 3N HCl) and 0.1 % w/v N-
naphthyl ethylenediamine dihydrochloride. The absorbace of 
the solutions were measered at 540 nm, 10 min after the 
addtion of Griess reagent against a blank solution containing 
5.00 ml of distilled water and 0.50 ml of Griess reagent. The 
concentrations of NO were calculated from the standard curve.  
A standard curve was prepared by using Sodium nitrite 
solution.A series of standard solution were prepared by mixing 
0.50 ml of freshly prepared Griess reagent with several aliquots 
of standard Sodium nitrate solution in graduated tubes. The 
volume of the tubes was then made up to 10.00 ml with 
phosphate buffer and the absorbance of the solutions was 
measured at 530 nm. The blank solution was prepared by 
mixing buffer and Griess reagent. Obsersed absorbances were 
plotted against concentrations to obtain the best-fit equation i.e. 
y=0.109x, where y=absorbance, x=concentration. The value of 
R
2
=0.997 & standard error mean (sem)=0.019.Shimadzu UV-
1800 Double Beam Spectrophotometer was used to measure 
the absorbance. 
 
Estimation of GSH level from the tissue homogenate samples 
Estimation of GSH was done per Ellman’s methods [29]. The 
level of GSH in the samples was determined at 2 h and 4 h of 
incubation. After each specified hour of incubation 1.00 ml of 
an incubated mixture was transferred into the centrifuge tubes 
(5 centrifuge tubes for each set, i.e. for C, D, DA, and A) and 
one ml of 5 % w/v TCA solution in 1 mM EDTA was added to 
each tube. Then the mixture was centrifuged at 3000 r.p.m for 
10 min and filtered to collect the supernatant. 1 ml of the 
filtrate was mixed with 5.00 ml of 0.10 M phosphate buffer 
(pH 8.0), and 0.40 ml of 5,5’-Dithiobis-(2-nitrobenzoic acid) 
(DTNB 0.01 % w/v in phosphate buffer) was added to it and 
the absorbance of the solutions was estimated at 412 nm.The 
blank solution was prepared from 6.00 ml of phosphate buffer 
and 0.40 ml of DTNB. The concentration of the test solutions 
was determined using standared curve, constructed as follows.  
 
Different aliquots of the standard GSH solution were taken in 
10.00 ml volumetric flasks. 0.40 ml of DTNB solution was 
added to each flask, and the volume was made upto the mark 
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with freshly prepared phosphate buffer (pH 8.0) solution. The 
absorbance was recorded at 412 nm, against a blank. The blank 
solution was prepared by using 9.60 ml of phosphate buffer and 
0.40 ml DTNB solution. Observed absorbances were plotted 
against concentrations to obtain the best-fit equation i.e. 
y=0.0005x, where y=absorbance, x=concentration. The value 
of R
2
=0.995 & standard error mean (sem)=0.011.Shimadzu 
UV-1800 Double Beam Spectrophotometer was used to 
measure the absorbance. 
 
RESULTS & DISCUSSIONS  
The lipid peroxidation induction capacity of Mahasudarshan 
churna was reported as average percentage (%) change in 
MDA (Table 1), NO (Table 2) and GSH (Table 3) 
concentration with respect to control group 
 
Table 1: Average % change in mda concentration with respect to control group 
After 4 h of incubation period After 2 h of incubation period 
Sets D DA A ANOVA Sets D DA A ANOVA 
1 
2 
3 
4 
5 
6 
7 
-3.73
a 
-3.68
a
 
-5.79
a
 
-7.36
a
 
-6.47
a
 
-8.07
a
 
-16.61
a 
-23.06
a
 
-14.29
a
 
-11.96
a
 
-14.70
a
 
-21.29
a
 
-23.17
a
 
-24.72
a
 
-6.45
a
 
-4.49
a
 
-3.47
a
 
-9.56
a
 
-12.54
a
 
-11.94
a
 
-18.92
a
 
F1=2.007 
(df=6,12) 
F2= 35.424 
(df=2,12) 
Critical 
difference: 
(p = 0.05)# 
Ranked mean** 
(D,DA,A) 
1 
2 
3 
4 
5 
6 
7 
-6.72
a
 
-10.20
a
 
-6.93
a
 
-6.52
a
 
-11.03
a
 
-5.79
a
 
-20.71
a
 
9.13
a
 
6.82
a
 
9.51
a
 
6.82
a
 
6.72
a
 
14.99
a
 
9.13
a
 
-12.22
a
 
-11.73
a
 
-10.54
a
 
-7.66
a
 
-12.11
a
 
-7.03
a
 
-12.22
a
 
F1=7.138 
(df=6,12) 
F2= 27.695 
(df=2,12) 
Critical 
difference: 
(p = 0.05)# 
Ranked mean** 
(D,DA,A) 
Mean 
±sem 
-7.39 
±0.39 
-19.03 
±0.51 
-9.63 
±0.46 
Mean 
±sem 
-9.70 
±0.93 
-21.98 
±1.06 
-10.09 
±1.35 
* Percent changes of D, DA and A with respect to controls of corresponding hours are shown in the Table. sem= Standard Error of 
Means of four sets (n=7).  Significance of ‘t’ values of the changes of MDA content (df = 2) are shown as: a > 99%. #Critical 
values of F at p = 0.05 level, F1 = 2.99 [df = (6, 12)], F2 = 3.88 [df = (2, 12)] at p=0.05. F1 and F2 corresponding to variance ratio 
between groups and within groups, respectively. **Two means are included within the same parenthesis, hence are not statistically 
significantly different at p = 0.05 level. 
 
Table 2: Average % change in no concentration with respect to control group 
After 4 h of incubation period After 2 h of incubation period 
Sets D DA A ANOVA Sets D DA A ANOVA 
1 
2 
3 
4 
5 
6 
7 
25.12
a 
4.14
a
 
13.81
a
 
29.04
a
 
20.46
a
 
16.64
a
 
14.42
a 
51.76
a
 
41.01
a
 
51.87
a
 
45.15
a
 
59.20
a
 
47.07
a
 
48.67
a
 
17.54
a 
13.38
a
 
8.44
a
 
25.49
a
 
10.68
a
 
14.06
a
 
11.05
a
 
F1=3.607 
(df=6,12) 
F2= 131.342 
(df=2,12) 
Critical 
difference: 
(p = 0.05)# 
Ranked mean** 
(D,DA,A) 
1 
2 
3 
4 
5 
6 
7 
26.03
a 
29.74
a
 
22.60
a
 
24.77
a
 
29.95
a
 
12.35
a
 
16.49
a 
53.73
a
 
63.52
a
 
50.62
a
 
49.37
a
 
56.77
a
 
56.62
a
 
37.45
a
 
18.60
a
 
17.12
a
 
17.55
a
 
10.92
a
 
10.82
a
 
6.81
a
 
2.95
a
 
F1=4.682 
(df=6,12) 
F2= 140.96 
(df=2,12) 
Critical 
difference: 
(p = 0.05)# 
Ranked mean** 
(D,DA,A) 
Mean 
±sem 
20.09 
±1.06 
48.67 
±1.43 
14.38 
±0.99 
Mean 
±sem 
23.14 
±1.15 
52.59 
±1.21 
12.11 
±1.23 
* Percent changes of D, DA and A with respect to controls of corresponding hours are shown in the Table. sem= Standard Error of 
Means of four sets (n=7).  Significance of ‘t’ values of the changes of NO content (df = 2) are shown as: a > 99%. #Critical values 
of F at p = 0.05 level, F1 = 2.99 [df = (6, 12)], F2 = 3.88 [df = (2, 12)] at p=0.05. F1 and F2 corresponding to variance ratio 
between groups and within groups, respectively. **Two means are included within the same parenthesis, hence are not statistically 
significantly different at p = 0.05 level. 
 
Journal of Applied Pharmaceutical Research 7 (2); 2019: 7 – 15 Pandit et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| April – June 2019 | Volume 7 Issue 2 |   11 
Table 3: Average % change in GSH concentration with respect to control group 
After 4 h of incubation period After 2 h of incubation period 
Sets D DA A ANOVA Sets D DA A ANOVA 
1 
2 
3 
4 
5 
6 
7 
21.95
a 
23.23
a
 
18.74
a
 
23.98
a
 
17.83
a
 
13.61
a
 
21.75
a 
50.85
a
 
54.94
a
 
46.29
a
 
51.97
a
 
45.42
a
 
50.15
a
 
55.00
a
 
26.40
a 
33.62
a
 
30.86
a
 
32.38
a
 
30.93
a
 
18.41
a
 
28.40
a
 
F1=3.253 
(df=6,12) 
F2= 168.30 
(df=2,12) 
Critical 
difference: 
(p = 0.05)# 
Ranked 
mean** 
(D,DA,A) 
1 
2 
3 
4 
5 
6 
7 
25.12
a 
37.82
a
 
15.31
a
 
20.28
a
 
19.85
a
 
16.82
a
 
20.73
a 
50.45
a
 
69.72
a
 
41.30
a
 
47.32
a
 
46.37
a
 
48.25
a
 
50.66
a
 
27.34
a
 
48.76
a
 
24.40
a
 
26.93
a
 
28.50
a
 
21.15
a
 
29.94
a
 
F1=44.153 
(df=6,12) 
F2=320.98 
(df=2,12) 
Critical 
difference: 
(p = 0.05)# 
Ranked 
mean** 
(D,DA,A) 
Mean 
±sem 
20.16 
±0.42 
50.66 
±0.80 
28.72 
±0.54 
Mean 
±sem 
22.24 
±0.81 
50.59 
±0.92 
29.58 
±0.66 
* Percent changes of D, DA and A with respect to controls of corresponding hours are shown in the Table. sem= Standard Error of 
Means of four sets (n=7).  Significance of ‘t’ values of the changes of GSH content (df = 2) are shown as: a > 99%. #Critical values 
of F at p = 0.05 level, F1 = 2.99 [df = (6, 12)], F2 = 3.88 [df = (2, 12)] at p=0.05. F1 and F2 corresponding to variance ratio 
between groups and within groups, respectively. **Two means are included within the same parenthesis, hence are not statistically 
significantly different at p = 0.05 level. 
 
Interpretation of the results was supported by Student “t” test. 
Analysis of variance (ANOVA) was performed on the % 
changes data of samples D, DA and A with respect to control 
group at 2 h and 4 h of incubation period [30-31]. Multiple 
comparison analysis and ANOVA was performed on the % 
changes in MDA, NO and GSH content to compare the means 
of the samples. There were no significant differences found 
among various groups of D, DA and A, statistically they are 
not different from each other.  
 
Lipid peroxidation is a common phenomenon occurs invariably 
in almost all the cells of living organisms. It serves as an 
instance of cells involving in free radical reaction by generating 
reactive oxygen species (ROS). Drug-induced toxicity was 
linked to peroxidation effects. In this work change of MDA, 
NO, and GSH content in goat liver samples was measured to 
quantify the lipid peroxidation induction potency of 
chemotherapeutic agents. The change in MDA, NO, and GSH 
content were observed after the specified time intervals and the 
results were verified by statistical analysis methods. The % of 
change in MDA, NO, and GSH level were calculated with 
respect to the corresponding control considered as the indicator 
of the extent of lipid peroxidation. It was observed that when 
the goat liver sample was treated with Mahasudarshan churna 
the MDA content decreased. This indicated the lipid 
peroxidation reduction capacity of the drug as MDA is a 
byproduct of lipid peroxidation. Groups where the sample was 
treated with Mahasudarshan churna and ascorbic acid both, the 
MDA content decreased in comparison with drug treated 
group. It suggested the synergistic effect of drug with ascorbic 
acid.  Groups which were treated with only ascorbic acid there 
was a decrease in MDA content compared to drug treated 
group. This was might be due to the fact that ascorbic acid can 
reduce the making of hydroxyl radicals and other reactive 
oxygen species through Fenton’s reaction. 
 
Nitric oxide (NO) is one of the most important biogenic 
molecules participates in many vital physiological processes 
within the mammalian body. It has both beneficial and harmful 
effects. The body should the appropriate levels of NO to 
protect the organs such as the liver from ischemic damage. 
Decrease in NO production results in tissue toxicity which may 
contribute to the vascular collapse associated with septic shock 
leads to inflammatory conditions including ulcerative colitis, 
multiple sclerosis, arthritis and juvenile diabetes. The results 
clearly shown that the level of NO increased in all the three 
samples, whereas the drug and antioxidant treated group 
showed the maximum increase in NO content. Again this was 
might synergistic effects of Mahasudarshan churna and 
ascorbic acid. This suggested that the drug is having lipidn 
peroxidation lowering capacity. 
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The average % changes in reduced glutathione (GSH) level of 
seven samples were showed that the level of GSH increased in 
all the three samples, whereas the drug and antioxidant treated 
group showed the maximum increase in GSH content. Again 
this was might synergistic effects of Mahasudarshan churna 
and ascorbic acid. This suggested that the drug is having lipidn 
peroxidation lowering capacity. 
Histograms of average % change in MDA, NO and GSH along 
with standard error mean were shown in Fig. 1, 2,3,4,5 and 6 
respectively. 
 
Fig. 1: Average % change in MDA content after 2 h of incubation period 
 
Fig. 2: Average % change in MDA content after 4 h of incubation period 
 
Fig. 3: Average % change in NO content after 2 h of incubation period 
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Fig. 4: Average % change in NO content after 4 h of incubation period 
 
Fig. 5: Average % change in GSH content after 2 h of incubation period 
 
Fig. 6: Average % change in GSH content after 4 h of incubation period 
 
CONCLUSION 
The central theme of this working hypothesis is laid behind the 
fact that the detectable changes of lipid in presence of drug in 
the body, changes in lipid constituents might be an important 
contribution to the therapeutic and toxic effect of the concern 
drug. The work was deigned to find out the lipid peroxidation 
induction capacity of Mahasudarshan churna and found that 
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lipid peroxidation is not the cause of toxicities produced by 
Mahasudarshan churna. The study revealed that there might be 
a different mechanism through which Mahasudarshan churna 
showed toxicity.  Lipid peroxidation is not the contributing 
factor of its toxicity. 
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